Drug firm Cipla on Monday said that it has received final nod from the US health regulator for its Medroxyprogesterone injectable for prevention of pregnancy.
The company has received final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Medroxyprogesterone injectable 150mg/mL.
The product is a generic version of Pfizer’s Depo-Provera. Depo-Provera and its generic equivalents had US sales of around USD 159 million for the 12-month period ending November 2018, Cipla said.
The injection is indicated only for the prevention of pregnancy. Shares of Cipla on Monday were trading at Rs 493.70 per scrip on the BSE, down 2.60 per cent from its previous close.